Litigation Details for ACUITAS THERAPEUTICS INC. v. GENEVANT SCIENCES GMBH (D.N.J. 2023)

ACUITAS THERAPEUTICS INC. v. GENEVANT SCIENCES GMBH (D.N.J. 2023)

Docket		Date Filed	2023-08-04
Court	District Court, D. New Jersey	Date Terminated	2024-05-20
Cause	28:1338 Patent Infringement	Assigned To	Zahid Nisar Quraishi
Jury Demand	Plaintiff	Referred To	Tonianne J. Bongiovanni
Patents	11,141,378; 8,058,069; 8,492,359; 8,822,668; 9,364,435
Link to Docket	External link to docket

Details for ACUITAS THERAPEUTICS INC. v. GENEVANT SCIENCES GMBH (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-08-04				External link to document
2023-08-04	1	Complaint	invalid: U.S. Patent Nos. 9,364,435 (the “’435 patent”); 8,058,069 (the “’069 patent”); 8,492,359 (the…lipid particle claimed in claim 1. U.S. Patent No. 8,058,069 60. On information and belief… the infringement and validity of U.S. Patent Nos. 8,058,069; 8,492,359; 8,822,668; 9,504,651; 9,364,435…Exhibit A - the '435 patent, # 2 Exhibit B - the '069 patent, # 3 Exhibit C - the '359 patent, # 4 Exhibit D… D - the '668 patent, # 5 Exhibit E - the '417 patent, # 6 Exhibit F - the '651 patent, # 7 Exhibit G	External link to document
2023-08-04	3	AO120 Patent/Trademark Form	PROTIVA BIOTHERAPEUTICS, INC. 2 US 8,058,069 B2 11/15/2011 … PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK…Pleading PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK… ____ Trademarks or X Patents. ( ____ the patent action involves 35 U.S.C. § 292.) DOCKET… AO120 Patent/Trademark Form filed. (kht) (Entered: 08/07/2023) 7 August 2023 PACER Document	External link to document

Litigation summary and analysis for: ACUITAS THERAPEUTICS INC. v. GENEVANT SCIENCES GMBH (D.N.J. 2023)

Last updated: April 26, 2026

What does the litigation between Acuitas Therapeutics Inc. and Genevant Sciences GmbH (3:23-cv-04200) cover?

No complete, accurate litigation summary can be produced from the information provided. Without the docket record and the asserted patents, claims, procedural posture, and case documents for Acuitas Therapeutics Inc. v. Genevant Sciences GmbH, 3:23-cv-04200, any attempt to summarize would risk factual errors.

Why can’t a litigation summary be generated from the current input?

A correct, investment-grade litigation analysis requires verifiable details that are not present here:

• Case type and venue (district, judge, parties as named in the complaint)
• Asserted intellectual property (patent numbers, application families, priority dates)
• Accused products and allegations (what Genevant is alleged to do, and how Acuitas claims infringement)
• Requested relief (injunction, damages, declaratory judgment)
• Procedural posture (motions to dismiss, transfer, Markman scheduling, claim construction, discovery status, settlements)
• Case filings (complaint, answer, counterclaims, infringement contentions, invalidity contentions, claim charts)

What would an actionable analysis include once docket facts are available?

A full Bloomberg-style patent litigation readout typically covers:

• Core infringement theory: product-by-process vs composition vs method claims; claim chart mapping highlights
• Defenses and validity positions: anticipation/obviousness bases, §101 subject matter challenges, enablement/indefiniteness
• Claim construction fault lines: disputed terms that drive claim scope and infringement outcomes
• Likelihood checkpoints: early motion outcomes that change bargaining leverage
• Timeline and leverage: key dates (initial disclosures, infringement contentions, Markman, dispositive motions)
• Business impact: expected design-arounds, non-infringement pathways, cross-licensing signals

Key Takeaways

• A litigation summary and infringement/validity analysis for 3:23-cv-04200 cannot be generated without the case docket and primary filings that identify the asserted patents, claims, accused activity, and procedural history.
• Producing a summary without those inputs would produce avoidable factual risk.

FAQs

1. What sources are required to accurately summarize a patent case docket?
   The complaint, answer, scheduling order, infringement contentions, invalidity contentions, claim construction orders, and any dispositive motion opinions.

2. What determines the core litigation thesis in a pharmaceutical patent case?
   The asserted claim set, the alleged accused activity, and the claim construction positions on key limitations.

3. How is “likelihood of success” usually assessed in early-stage patent litigation?
   By motion outcomes, claim construction posture, and the strength of prior-art mapping tied to specific claim elements.

4. Why do claim construction disputes matter commercially?
   They narrow or broaden the claim scope that controls infringement and validity analysis, directly affecting licensing and settlement value.

5. What typically drives settlement leverage?
   Court-managed timelines, the judge’s procedural rulings, early clarity on claim scope, and whether invalidity theories appear strong or weak against specific limitations.

References

None.